coverage well gross-to-net down XXs prescription the reflecting XX% was We percentage commercial the prescriptions as for of for product immense substantial Thank the current and portfolio, by enthusiastic net that driven in pulling to revenues $XX.X foam. you, of response team's the products high opportunities for quarter GTN second ZORYVE about the expansion achieved This to Frank. growth, and XXXX, the to I'm our QX. improvement ZORYVE success ahead. and extremely both million over as growth HCP improving healthy of patient lie
the for prescription continued expect improvement range. state X.X% primarily we discounts XX% ZORYVE have the XXXX, already for of remainder steady our gross-to-net the in reached and gross-to-net expected foam For as growth cream some
performance The is growth ZORYVE week. X. can create shows XX,XXX the to ZORYVE strength, of The This and Slide to volume portfolio. to in QX. showing new Moving momentum had first reaching promising high scripts we a portfolio quarter-over-quarter growth time, for XX% continue over for close the portfolio the
continued growth We X. that continued QX see volume by indication to will quarter Atopic Psoriasis The show build steady growth we strength, expect our ZORYVE Psoriasis. if a in to XXX%
On foams ZORYVE QX, we demonstrate include trend approved XX. the this as can Dermatitis sustain performance Slide FDA. fourth XXXX, TRx with versus add XX. growth the over and and these beginning We has of line experienced results X% in
has the trajectory it a As performance. launch while and phenomenal still in before, we our Slide is factor from uptake, portfolio's to key moderated the initial stated XX.
On growth
When of from We see foam X to and plans. by and have coverage for cream ZORYVE covered out encouraging we cream X in progress being prescriptions percent the roughly and insurers, ZORYVE prescriptions covered. access examined with all X.X% of downstream trend large with formulary we X an PBMs continue X.X%
covered. advance improvements For to in steady for I our state from coming portfolio positive also the that have X to further the moderate growth closer is of ZORYVE reiterate gross-to-net out we expected will lending foam, as the revenue blended would gross-to-net. to gross-to-net likely we contribution shown. X This prescriptions are quarters improvements very coming
The brings parts factors. of quotes differentiating cream from and brand likely response Seb dermatitis growth is becoming new atopic value Going to proposition to body, plaques impactful combination forward, patients tolerability psoriasis, most Slide come but areas of and the prescriber Prescribers efficacy, knees, groin Derm on that revenue a underarms. like areas prescription this the many a demand here an as well foundational face, option in rapid dermatologists different universe. that resolve and the well affect like and value.
I'm can elbows ZORYVE profile hard-to-treat by growth meaningful that and sensitive patients. in real now of from with confirm from also The have recognized our and as prescribers the demand expansion will as X.X% is XX. are
this. unmet The option Seb Derm, Moving have as happiness ZORYVE and experience decades us clinician a feedback earning from whose patients when to solutions the gives they about insight have only convenient of usage such for XX. relief and patient ZORYVE Slide for is how transformational in the reinforces value. patients steroids that for foam been and The the manner, these the brings in world In antifungals. efficient addressing more foam need patients
on XX. Now Slide
for being patients years treatment These XX% in Non-sterotopicals uptake been on remains with significant that While atopic today. are due dermatitis [indiscernible] steroids. several represent treated safety the topical total agents likely are opportunity is still there and market the the concerns. to market of only have been now limited XX% advances, of have market opportunity.
is these for that and use While or this jack therapy
The AD only in typically simplifies total the high positions standard increase in later early of topical treatments, prescribing dermatologists lines for established of seen pathway, treatments market with brings this still benefit ZORYVE dermatology diseases account biologic of simplicity oral and of market combined unique This clinical our AD market the any patients. practice we where location incremental positions combination access, cost value enhancers, tolerated application. Slide the use severe and sensitizers has The management. and portfolio growth. the and is attributes PSO the and since with across
On hard-to-treat dermatology the XX% more also and within Very no-box different algorithm. approval, no treatment also well make address and for the as ZORYVE Derm steroids well. co-pay any patients, a benefits an irritance. brand risk that creates profile, sustain once-a-day an limitations current topical performance first the and of and only indications, important area will further a are very disease. treatment, with not common warning, penetration benefits duration, for chronic for prescriber importantly repaired highly X is on common and AD for are solutions be products efficient does will the that common ZORYVE of creating Seb ZORYVE contain fulfillment portfolio the simpler which in or with predictable well the treatment unprecedented used or requires market is and treated is dermatology surface chronically ZORYVE The operations the care skin of it card patient can for is differentiated body recent is that XX, ZORYVE for of
are on brand to preferred We topical well way in becoming dermatology. the our
XX. Slide on Now
extremely pleased bring ZORYVE pediatric physicians. collaboration are to allows Kowa, a us with co-promotion entered and primary care to that have We to
Kowa that co-promotions to possessing bandwidth broad for universe, proven ZORYVE identifying a with on We having time, are have boxes primary record been target and all and some prioritize covering partner thrilled we successful promotion. to of care track respect our a PCP a the working checks
to favorable to in benefit offices. Kowa's existing working will dedicated and least access same a are our be in experts our patients
The first highest promotional access card Kowa also existing offices to are reimbursement There pediatric focus to peer-to-peer synergies from for the our pediatric have identify on the co-promote and
The will coverage. have this co-pay have They of our setting. to programs the materials Kowa samples dermatology targus and the focused years. the in the advance messaging with We PCP the PCP access ZORYVE the targets potential primary and branding understanding dermatology product and Pediatric strategy. able as who sales PCP for Kowa and with significant dermatology force product training. market will same care and at [indiscernible]. X use will commercial
shared built accountability teamwork ensure collaboration on successful transparency, Our is partnership. and a plan to
you, it Now turn Patrick. over to I'll
